BETHLEHEM, Pa.--(BUSINESS WIRE)--Saladax Biomedical, Inc. (www.saladax.com), a personalized medicine diagnostics company pioneering the development of Personalized Chemotherapy Management (PCM®) assays to test blood levels of the most commonly used anti-cancer medicines, has signed an agreement with Lab21 for supply of testing services in the United Kingdom, Ireland and the Middle East.
